Floatz logo

Sorafenib

Portal Vein Tumor Thrombosis

Zhongda HospitalSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Portal Vein Tumor Thrombosis cohort.

Asset / SponsorPhaseRating
Lipotecan
Taiwan Liposome Company
Phase 1/2CC
Ethiodized Oil
Zhongda Hospital
N/AD
Theprubicin
Zhongda Hospital
N/AD

Same molecule, other indications

Sorafenib is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
79 / 100
View asset →
SorafenibDormant
BBB
Indicative ·
75 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →